Skip to main content
. 2019 Jun 22;86(2):215–224. doi: 10.1002/ana.25513

Table 2.

Patient Demographics of All Subjects Combined ABBY and BLAZE Studies

Characteristic 15mg/kg Crenezumab IV Every 4 Weeks, n = 198 300 mg Crenezumab SC Every 2 Weeks, n = 148 Placebo, n = 176
Age, yr (SD) 71 (6.9) 70.4 (7.1) 70 (7.2)
Sex, F (%) 106 (53.5%) 80 (54.1%) 92 (52.3%)
MMSE mean score (SD) 21.7 (2.7) 21.7 (2.7) 21.5 (2.5)
MMSE score 22–26, n (%) 101 (51%) 70 (47.3%) 82 (46.6%)
APOE ε4 carriers, n (%) 139 (70.2%) 100 (67.6%) 124 (70.5%)
ADAS‐Cog12 mean score (SD) 29.3 (9.3) 28.4 (8.7) 28.5 (8.8)
CDR‐SB mean score (SD) 4.6 (2.1) 4.6 (1.9) 4.6 (2.1)
ADCS‐ADL mean score (SD) 64.2 (10.4) 64.6 (9.5) 64.9 (10.1)

ADAS‐Cog12 = Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS‐ADL = Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory; CDR‐SB = Clinical Dementia Rating–Sum of Boxes; F = female; IV = intravenous; MMSE = Mini‐Mental State Examination; SC = subcutaneous; SD = standard deviation.